Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.
There are only few reports regarding the role of lifetime drug or substance use in multiple sclerosis (MS) etiology. In this study, we investigated the potential effect of drug or substance exposure on the onset of MS diagnosis. We conducted a population-based incident case control study in Tehran....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5916854?pdf=render |
id |
doaj-49ca5a023bb34f2ba8458280bf973ea2 |
---|---|
record_format |
Article |
spelling |
doaj-49ca5a023bb34f2ba8458280bf973ea22020-11-25T02:08:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01134e019624410.1371/journal.pone.0196244Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.Ibrahim AbdollahpourSaharnaz NedjatMohammad Ali MansourniaTibor SchusterThere are only few reports regarding the role of lifetime drug or substance use in multiple sclerosis (MS) etiology. In this study, we investigated the potential effect of drug or substance exposure on the onset of MS diagnosis. We conducted a population-based incident case control study in Tehran. Cases (n = 547) were 15-50 years old persons with MS identified from the Iranian Multiple Sclerosis Society (IMSS) register during August 7, 2013, and November 17, 2015. Population-based controls (n = 1057) were 15-50 years old and were recruited by random digit telephone dialing. Inverse-probability-of-treatment weighing (IPTW) using two sets of propensity scores (PSs) was used to estimate marginal incidence odds ratios (ORs) for MS contrasting pre-specified substance use. The estimated marginal OR was 6.03 (95% confidence interval: 3.54;10.3, using trimmed weights at the 95th percentile of the stabilized weight distribution) in both IPTW analyses comparing lifetime substance use (opioids, cannabis, inhalants, hallucinogens and stimulants) for at least one time monthly during a six-months or longer period vs. no such history of drug use. Subject to limitation of causal claims based on case-control studies, this study suggests that monthly drug or substance use for a period of at least six consecutive months, may increase the risk of MS by factor 3.5 or higher.http://europepmc.org/articles/PMC5916854?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ibrahim Abdollahpour Saharnaz Nedjat Mohammad Ali Mansournia Tibor Schuster |
spellingShingle |
Ibrahim Abdollahpour Saharnaz Nedjat Mohammad Ali Mansournia Tibor Schuster Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. PLoS ONE |
author_facet |
Ibrahim Abdollahpour Saharnaz Nedjat Mohammad Ali Mansournia Tibor Schuster |
author_sort |
Ibrahim Abdollahpour |
title |
Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. |
title_short |
Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. |
title_full |
Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. |
title_fullStr |
Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. |
title_full_unstemmed |
Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population. |
title_sort |
estimation of the marginal effect of regular drug use on multiple sclerosis in the iranian population. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
There are only few reports regarding the role of lifetime drug or substance use in multiple sclerosis (MS) etiology. In this study, we investigated the potential effect of drug or substance exposure on the onset of MS diagnosis. We conducted a population-based incident case control study in Tehran. Cases (n = 547) were 15-50 years old persons with MS identified from the Iranian Multiple Sclerosis Society (IMSS) register during August 7, 2013, and November 17, 2015. Population-based controls (n = 1057) were 15-50 years old and were recruited by random digit telephone dialing. Inverse-probability-of-treatment weighing (IPTW) using two sets of propensity scores (PSs) was used to estimate marginal incidence odds ratios (ORs) for MS contrasting pre-specified substance use. The estimated marginal OR was 6.03 (95% confidence interval: 3.54;10.3, using trimmed weights at the 95th percentile of the stabilized weight distribution) in both IPTW analyses comparing lifetime substance use (opioids, cannabis, inhalants, hallucinogens and stimulants) for at least one time monthly during a six-months or longer period vs. no such history of drug use. Subject to limitation of causal claims based on case-control studies, this study suggests that monthly drug or substance use for a period of at least six consecutive months, may increase the risk of MS by factor 3.5 or higher. |
url |
http://europepmc.org/articles/PMC5916854?pdf=render |
work_keys_str_mv |
AT ibrahimabdollahpour estimationofthemarginaleffectofregulardruguseonmultiplesclerosisintheiranianpopulation AT saharnaznedjat estimationofthemarginaleffectofregulardruguseonmultiplesclerosisintheiranianpopulation AT mohammadalimansournia estimationofthemarginaleffectofregulardruguseonmultiplesclerosisintheiranianpopulation AT tiborschuster estimationofthemarginaleffectofregulardruguseonmultiplesclerosisintheiranianpopulation |
_version_ |
1724927642989232128 |